XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaborations with Third Parties (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 02, 2024
Apr. 17, 2020
Jan. 02, 2019
May 31, 2024
Apr. 30, 2021
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2020
Collaborations with Third Parties                    
First milestone payment $ 100,000                  
Time required to pay cash portion 15 days                  
Second milestone payment $ 25,000                  
Collaboration revenue           $ 73,834 $ 25,786 $ 211,569 $ 50,115  
Collaboration revenue                    
Collaborations with Third Parties                    
Collaboration revenue       $ 25,000   45,532 5,493 158,511 12,791  
Minimum                    
Collaborations with Third Parties                    
Aggregate payment agreement $ 125,000                  
Daiichi Sankyo Europe GmbH ("DSE") | Collaboration revenue                    
Collaborations with Third Parties                    
Collaboration revenue           45,400 5,300 158,400 12,400  
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement                    
Collaborations with Third Parties                    
Upfront cash payment received (paid)     $ 150,000              
Cash payment to the Company upon first commercial sales in the DSE Territory                   $ 150,000
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Minimum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales     15.00%              
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Maximum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales     25.00%              
Otsuka Pharmaceutical Co, Ltd. | Collaboration revenue                    
Collaborations with Third Parties                    
Collaboration revenue           100 0 100 0  
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities                    
Collaborations with Third Parties                    
Upfront cash payment received (paid)   $ 60,000                
Potential additional future payments   $ 450,000                
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Minimum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales   15.00%                
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Maximum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales   30.00%                
Milestone payment, first JNDA submissions   $ 20,000                
Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory   70,000                
Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label   50,000                
Milestone payments related to total net sales achievements   $ 310,000                
Daiichi Sankyo Co. Ltd | Collaboration revenue                    
Collaborations with Third Parties                    
Collaboration revenue           $ 100   $ 100    
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement                    
Collaborations with Third Parties                    
Collaboration revenue             $ 200   $ 400  
Consideration cash payment         $ 30,000          
Cash payment to be received upon certain commercial milestones         $ 175,000          
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Minimum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales         5.00%          
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Maximum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales         20.00%